- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
No shortage of TB drugs in India: Govt
New Delhi: The Ministry of Health & Family Welfare has informed that there is no shortage of anti-tuberculosis drugs in the country. There has been regular supply of Anti-TB drugs to all the State/UTs from the central level under the National TB Elimination Programme (NTEP) throughout the year and regular assessments are conducted to evaluate the stock positions at various levels,...
New Delhi: The Ministry of Health & Family Welfare has informed that there is no shortage of anti-tuberculosis drugs in the country. There has been regular supply of Anti-TB drugs to all the State/UTs from the central level under the National TB Elimination Programme (NTEP) throughout the year and regular assessments are conducted to evaluate the stock positions at various levels, from central warehouses to peripheral health institutes.
Further, State/UTs have been provisioned with resources for local procurement for limited quantities as and when required to meet the emergent requirements.
The details of stock positions of anti-tuberculosis drugs placed are as under:
Stock of Anti TB Drugs as on 06-12-2023 | ||
Drug Name | Total Stock available | Stocks will last (approx. months) |
Tab. 2FDC (P) (H50 & R75) | 18078984 | More than 6 months |
Tab.3FDC CP (A) (H75,R150 & E275) | 159287016 | For 4 months |
Tab 3FDC(P) (H50, R75, Z150) | 17889844 | More than 6 months |
Tab. 4FDC(A) (H75, R150, Z400 & E275) | 94250072 | For 4 months |
Tab. Bedaquiline (BDQ)-L | 9835849 | More than 6 months |
Cap. Clofazimine 100mg | 7901607 | More than 6 months |
Cap. Clofazimine 50mg | 129405 | More than 6 months |
Cap. Cycloserine 250mg | 12591104 | More than 6 months |
Tab. Delamanid 50mg | 3688946 | More than 6 months |
Tab. Ethambutol 100mg | 40895959 | More than 6 months |
Tab. Ethambutol 800mg | 2759910 | For 3 months |
Tab. Ethionamide 250mg | 15096309 | More than 6 months |
Tab. Moxifloxacin 400mg | 25720793 | More than 6 months |
Tab. Isoniazid 300mg | 43951761 | More than 6 months |
Tab. Levofloxacin 250mg | 10770158 | More than 6 months |
Tab. Levofloxacin 500mg | 9862422 | More than 6 months |
Tab Linezolid 600mg | 4190760 | More than 6 months |
Tab. Pyrazinamide 500mg | 6262558 | More than 6 months |
Tab. Pyrazinamide 750mg | 5862684 | More than 6 months |
Tab. Pyridoxine 100mg | 20060750 | More than 6 months |
Tuberculosis (TB) is an infectious disease that most often affects the lungs and is caused by a type of bacteria. It spreads through the air when infected people cough, sneeze or spit. Tuberculosis is preventable and curable.
According to WHO, about a quarter of the global population is estimated to have been infected with TB bacteria. About 5–10% of people infected with TB will eventually get symptoms and develop TB disease. Those who are infected but not (yet) ill with the disease cannot transmit it. TB disease is usually treated with antibiotics and can be fatal without treatment.
Read also: Vague and ill-informed: Centre dismisses claims on shortage of anti-TB drugs in India
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751